Cost-Effectiveness of Pregabalin, Duloxetine, and Milnacipran vs Amitriptyline for Moderate to Severe Fibromyalgia
In this decision analytical model, duloxetine 120 mg was the preferred strategy across perspectives; pregabalin 450 mg was economically favorable relative to amitriptyline only when societal costs were included. Amitriptyline provided greater net benefit than milnacipran and the lower doses of pregabalin and duloxetine. These findings may help inform the selection of value-based treatments for moderate to severe FM.
Authors
- Ismaeel U. Yunusa (ORCID: https://orcid.org/0000-0002-9107-8561)
- K. Ben-Umeh
- Tewodros Eguale (ORCID: https://orcid.org/0000-0002-8268-0884)
- H Farag
- Abby Davies (ORCID: https://orcid.org/0009-0007-0756-8159)
- Sarah S. Downen
- Chijioke M. Okeke
Institutions
- University of South Carolina (US)
- Massachusetts College of Pharmacy and Health Sciences (US)
- University of Utah (US)
- University of Florida (US)
- Soliman Fakeeh Hospital (SA)
- University of Houston (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.57536
- Primary Topic
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00